Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Int J Clin Oncol. 2018 Apr;23(2):258-265. doi: 10.1007/s10147-017-1206-y. Epub 2017 Nov 4.
This study compared the differences between the estimated glomerular filtration rate (eGFR) calculated by several equations based on serum creatinine (Scr) and cystatin C (CysC) concentrations for monitoring renal function in patients with small-cell lung cancer (SCLC) during chemotherapy.
Seventy-one patients with SCLC were retrospectively analyzed. The eGFR before and after each chemotherapy cycle was calculated by the following equations: the chronic kidney disease epidemiology collaboration (CKD-EPI) equation, the modification of diet in renal disease (MDRD) equation, the Cockcroft-Gault (CG) equation, and five CysC-based equations. The patients were compared among the different eGFR groups.
The mean decreases in eGFR (-2.25 ± 9.89 ml/min/1.73 m) between each treatment cycle were more significant than the decreases in eGFR (-0.46 ± 10.17 ml/min/1.73 m), eGFR (-0.48 ± 9.79 ml/min/1.73 m), and five calculated eGFR (p < 0.05). Single-/multiparameter analyses showed that patients with a higher body mass index (BMI >23) and receiving more treatment cycles (>3) were at increased risk for developing renal impairment with an eGFR less than 60 ml/min/1.73 m during chemotherapy.
The eGFR calculated by the CKD-EPI equation changed more significantly between each chemotherapy cycle than did the eGFR from the other equations based on Scr or CysC in patients with SCLC. Oncologists should pay more attention to the renal function of specific patient groups during treatment.
本研究比较了基于血清肌酐(Scr)和胱抑素 C(CysC)浓度的几种方程估算肾小球滤过率(eGFR)在小细胞肺癌(SCLC)患者化疗期间监测肾功能的差异。
回顾性分析 71 例 SCLC 患者。采用慢性肾脏病流行病学合作(CKD-EPI)方程、肾脏病饮食改良(MDRD)方程、 Cockcroft-Gault(CG)方程和 5 种 CysC 方程分别计算每个化疗周期前后的 eGFR。比较不同 eGFR 组患者之间的差异。
每个治疗周期 eGFR 的平均下降(-2.25±9.89 ml/min/1.73 m)明显大于 eGFR 的下降(-0.46±10.17 ml/min/1.73 m)、eGFR 的下降(-0.48±9.79 ml/min/1.73 m)和 5 种计算的 eGFR(p<0.05)。单因素/多因素分析显示,BMI>23 的患者和接受更多治疗周期(>3 个)的患者在化疗期间发生 eGFR<60 ml/min/1.73 m 的肾功能损害的风险增加。
在 SCLC 患者中,与基于 Scr 或 CysC 的其他方程相比,CKD-EPI 方程估算的 eGFR 在每个化疗周期之间的变化更为明显。肿瘤学家在治疗过程中应更加关注特定患者群体的肾功能。